MET and non-small cell lung carcinoma: In addition, in the c-Met-dysregulated NSCLC cohort, the response to c-Meti in the SYKlow subtype was inconsistent; there was one case of PD (indicating resistance) and 4 cases of SD (indicating clinical benefit) in this cohort.